The guidelines address the following opportunistic infections: PCP, Toxo, Cryptosporidia, Microsporidia, TB, MAC, Bacterial Respiratory Disease, Bacterial Enteric Disease, Bartonella, Syphilis, Candida, Endemic Mycoses (Cryptococcosis, Histo, Cocci, Aspergillus) CMV, Non-CMV Herpes (HSV, VZV, HHV-8) HPV, HBV, HCV, PML/JCV, and Geographic OIs of Specific Consideration (Malaria, Penicilliosis, Leishmania, Chagas, Isospora).
Recommendations in this report cover:
|Preventing exposure to opportunistic pathogens; |
|Preventing disease; |
|Discontinuing primary prophylaxis after immune reconstitution;|
|Treating disease; |
|When to start ART in the setting of an acute OI;|
|Monitoring for adverse effects (including immune reconstitution inflammatory syndrome [IRIS]);|
|Managing treatment failure;|
|Preventing disease recurrence ("secondary prophylaxis" or chronic maintenance therapy);|
|Discontinuing secondary prophylaxis after immune reconstitution; and |
|Special considerations during pregnancy.|
Slide sets to accompany the guidelines are available from the National Resource Center.